Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Bevacizumab for CNV Secondary to AMD
NCT00556348Phase 4Completed
- Sponsor
- Instituto de Olhos de Goiânia
- Start
- Nov 2005
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab in age-related macular degeneration (AMD) and choroidal neovascularization (CNV), sponsored by Instituto de Olhos de Goiânia. Primary endpoints: Vision change at 2 months, Anatomical changes at 2 months and 1 more. Started Nov 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
age-related macular degeneration (AMD)choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00556348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00556348.